Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia
Sergi Pascual-Guardia1, Francesco Amati2, Judith Marin-Corral3
1Respiratory Department, Hospital del Mar-IMIM, CEXS, UPF, CIBERES, BRN, Barcelona, Spain; Division of Pulmonary Diseases & Critical Care Medicine, University of Texas Health San Antonio, San Antonio, TX,USA.
This study identifies key risk factors for Pseudomonas aeruginosa in chronic obstructive pulmonary disease (COPD) patients with community-acquired pneumonia (CAP). A new scoring system can significantly reduce unnecessary anti-pseudomonal antibiotic use in these patients.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Clinical Microbiology
Background:
- Community-acquired pneumonia (CAP) is a frequent complication in patients with chronic obstructive pulmonary disease (COPD).
- Limited data exist on risk factors for difficult-to-treat pathogens like Pseudomonas aeruginosa in COPD patients with CAP.
- Understanding microbiological patterns is crucial for optimizing empiric antibiotic therapy.
Purpose of the Study:
- To assess microbiological patterns in hospitalized COPD patients with CAP.
- To identify risk factors associated with specific microorganisms, particularly Pseudomonas aeruginosa.
- To develop a scoring system to guide empiric anti-pseudomonal antibiotic therapy decisions.
Main Methods:
- Secondary analysis of an international, multicenter, observational, point-prevalence study.
- Inclusion of 689 hospitalized COPD patients with CAP and documented microbiological testing.
- Development of a scoring system based on independent risk factors for P. aeruginosa.
Main Results:
- The most common isolates were Streptococcus pneumoniae (8%), Gram-negative bacteria (8%), P. aeruginosa (7%), and Haemophilus influenzae (3%).
- Key risk factors for P. aeruginosa included prior isolation/infection (OR 14.2), hospitalization within 12 months (OR 3.7), and bronchiectasis (OR 3.2).
- The developed scoring system has the potential to decrease empiric anti-pseudomonal antibiotic use from 54.1% to 6.2%.
Conclusions:
- COPD patients with CAP exhibit distinct microbiological profiles and associated risk factors.
- Empiric anti-pseudomonal antibiotic selection is a critical therapeutic decision.
- A novel COPD scoring system is proposed to aid in guiding empiric anti-pseudomonal antibiotic therapy.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...